A maladaptive pathway to drug approval
The European Medicines Agency (EMA) has embraced a new model of drug testing and marketing called “adaptive pathways”, allowing new drugs for “unmet medical needs” to be launched on the market faster, on the basis of fewer data.
While industry claims this is necessary, an analysis on thebmj.com looks at the assumptions underlying the new pathway,...